Smith & Nephew Share Discussion Threads

[essentialinvestor] 05/2/2019 17:03

Nice day. Helped by the UKX and FX - weaker GBP.

[abbynat] 05/2/2019 16:56

onwards and upwards! back over the £15.00 mark?

[essentialinvestor] 05/2/2019 09:59

Bought a few more SN. Under 1433.
Unsure how the market will react so it's a small position,
would have liked it closer to £13-13.50,
which may be available if the update disappoints.

[essentialinvestor] 01/2/2019 12:08

The recent Stryker results show what can be achieved with a decent CEO.

Think there is a case to me made for selling wound care myself.

[kknight01] 12/12/2018 11:12

Strange. Nothing spectacular regarding last results. Forecast looks on target and inline with sector. New CEO is 6months in now so is likely going to start making significant change anytime, perhaps Market are expecting good things from Namal.

[steeplejack] 07/12/2018 14:28

Stock up a short 20% in just over 6 weeks in weak market.Bid?

[essentialinvestor] 02/11/2018 11:03

Pleased to see the back of Olivier, debatable what he actually achieved.
Some very highly priced acquisitions which failed to live up to high expectations?.

[broadwood] 02/11/2018 08:33

Global medical technology business Smith & Nephew reported a 3% increase in third-quarter underlying revenue and reconfirmed its full-year guidance as it implemented a new global commercial model.

The firm said on Thursday that growth in its US and Emerging Markets segments had supported the 3% increase to $1.169bn,

"We expect underlying revenue growth to be in the lower half of the 2-3% range and, as a result of a favourable legal settlement and improved cost control, trading profit margin to be above that achieved in 2017," CEO Namal Nawana said.

However, revenue declined 1% in its Other Established Markets, where Europe was negatively impacted by challenging conditions in Germany and the UK, while revenue from its Advanced Wound Bioactives franchise fell 7%.

Looking forward, the Group did not believe the UK's decision to leave the EU would have a significant impact on its long-term ability to conduct business into and out of the EU or UK. It was making "good progress" with preparations of the various scenarios.

In order for the company to leverage its strength as a portfolio medical device company and unlock its growth potential, it was implementing a new global commercial model. Under this, a president would be responsible for each of its three specialised global marketing franchises - Orthopaedics, Sports Medicine/ENT and Wound. Aligned with and supporting the franchises would be presidents and regional commercial organisations for Europe, Middle East, and Africa (EMEA), and Asia Pacific (APAC), while the franchise presidents would also have commercial responsibility for the US.

[broadwood] 01/11/2018 08:23

Market likes.

Improved underlying revenue growth in the third quarter was led by growth in the US and Emerging Markets. We are on-track to deliver our full year guidance.

"These results were achieved whilst successfully redesigning how we will run the company. There is still more to do, and I am pleased with the pace of progress and engagement across the organisation."

If there's a bidder lurking, nows the time.

[pugugly] 26/7/2018 07:42

Accounts our for 1/2 year - Very much steady as she goes -

Nothing to shout about (imo) share price reaction will very much depend on forecasts (anyone got them?)

[steeplejack] 04/5/2018 08:24

Elliott called for the company to be broken up last year, after which Mr Bohuon unveiled a cost-cutting plan which he said would deliver $160m of savings by 2022.Analysts at Bernstein said: "S&N's overall performance on both growth and margins has remained disappointing. From here it is all about execution." Daily Telegraph

[its the oxman] 03/5/2018 10:49

Yes , got to be only a matter of time.

[basil brush1] 03/5/2018 09:28

Something has to happen here. These guys are vulnerable now. Would not be surprised if Elliot Management makes a return.

[broadwood] 03/5/2018 08:25

These less than brilliant results would make it an opportune time to strike for a possible bidder.

[steeplejack] 03/5/2018 08:17

The guidance has been trimmed from revenue growth of 3-4% at the time of the finals to 2-3% now.The suggestion is that things will stabilise and return to a more normal pattern in the rest of the year.Emerging markets are encouraging.Whether this update is worth over 7% off the share price is questionable especially given the corporate activity just now in the sector.Yet the shares have been very strong of late and are vulnerable to top slicing.Maybe I'm too simplistic but I never really worry about my holding in Smith & Nephew.I always feel that if things take an enduring turn for the worse,someone will take the company over.

[basil brush1] 03/5/2018 07:43

I think you are too pessimistic. I am seeing a P/E of 20 on 2018 EPS before this update, while Stryker is 26. Emerging markets growing at 9% and SN has very little debt.

[rock star] 03/5/2018 07:25

Flat earnings and a P/E of 22 hardly makes it remotely attractive. Also I see plenty of alternative wound care therapies coming through in coming years. Look at Origin WW as an example. Technology been given fast track approval by FDA.

[broadwood] 23/4/2018 19:35

I bought these on the bid speculation awhile back.

This sounds interesting.




Smith & Nephew was top of the blue chip pile as Dutch giant Philips' first-quarter results revealed strong growth in medical equipment, which was music to the ears of the London-listed maker of artificial shoulders, knees and possibly toes.

A further tonic for S&N shares was bid speculation bubbling up again as City traders pointed to US-based Stryker, based in the marvellously named Kalamazoo, Michigan, being a possible suitor after four years ago confirming it had been been looking at a potential takeover.

[its the oxman] 23/4/2018 15:48

Why today? News?

[basil brush1] 23/4/2018 15:43

Is this the big breakout?

[basil brush1] 04/4/2018 16:13

Any views on new CEO? He sold Alere to Abbott in 2017 for $5.3 billion. No one seems to care?

[its the oxman] 24/1/2018 08:00

Scope to have a run back over 1300p with lower tax guidance.

[basil brush1] 22/1/2018 10:20

Strykers full results are on Jan 30, the next few weeks will be interesting.


Stryker provides 2017 preliminary net sales results
By GlobeNewswire, January 09, 2018, 08:15:00 AM EDT

Kalamazoo, Michigan - January 9, 2018 - Stryker Corporation (NYSE:SYK) announced today that preliminary results for the fourth quarter and full year 2017 were:

Preliminary Fourth Quarter Highlights

Net sales grew 10.0% to $3.5 billion (8.7% constant currency)

Orthopaedics 8.1 % or 6.8 % constant currency
MedSurg 10.9 % or 9.8 % constant currency
Neurotechnology and Spine 11.5 % or 10.3 % constant currency
Preliminary Full Year Highlights

Net sales grew 9.9% to $12.4 billion (9.8% constant currency)

Orthopaedics 6.6 % or 6.5 % constant currency
MedSurg 13.6 % or 13.4 % constant currency
Neurotechnology and Spine 8.2 % or 8.3 % constant currency
Preliminary consolidated net sales of $3.5 billion and $12.4 billion increased 10.0% and 9.9% as reported in the fourth quarter and full year. Excluding the impact of foreign currency and acquisitions, net sales increased 8.1% and 7.1% in the fourth quarter and full year.

Based on our year-to-date performance, we expect 2017 adjusted net earnings per diluted share(a) to be toward the high end of our previously announced range of $6.45 to $6.50. The foreign currency exchange impact on net sales in the fourth quarter was positive of approximately 1.2% and nominal in the full year.

"We continued our momentum with strong organic sales growth of 8% for the fourth quarter and 7% for the full year," said Kevin A. Lobo, Chairman and Chief Executive Officer. "I would like to thank our teams for delivering these results, which were well balanced across businesses and geographies. We are also driving innovation through R&D and acquisitions that will fuel future growth. These investments will enable us to deliver sales growth at the high end of med tech and leveraged earning gains."

[basil brush1] 22/1/2018 10:16

Good luck! IMO these UK companies that report in foreign currencies lose out both ways, because the US investors dont understand the accounting while the UK investors are confused by the currency. SN has fallen nearly £2 since October, the market seems to be discounting the worst. But meanwhile Stryker keeps marching on.

[its the oxman] 21/1/2018 12:42

Bloody well hope there is a bid. Sold a load just under 1400p and now bought them back and more besides. Poor performer over 12 months. Hoping for a bounce regardless with results. We will see.